Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

The Mukaab's architectural inspiration is drawn from Saudi Arabia's traditional and natural heritage. Saudi Arabia has begun work on a monumental $50-billion megastructure in Riyadh, aiming to ...

In an ambitious move to reshape its urban landscape, Saudi Arabia has launched a staggering $50 billion project known as the ‘Mukaab’. Located in the capital city of Riyadh, construction has commenced ...

(Also read: ₹100,000 for classic Indian chappal? Viral video from Saudi Arabia shocks people) Construction is being overseen by Saudi’s New Murabba Development Company (NMDC), a key player ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

It’s an out-of-the-box undertaking. Ground has officially been broken in Saudi Arabia for what is expected to be the “world’s largest building.” The ambitious, $50 billion project ...

It’s an out-of-the-box undertaking. Ground has officially been broken in Saudi Arabia for what is expected to be the “world’s largest building.” The ambitious, $50 billion project — called the Mukaab ...

As the Lower House election approaches this Sunday, a barrage of articles profuse with political labels is appearing in the media. But none of the articles explain what the labels mean ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...